Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings yield is N/A as of 2026-10-06T16:28:24.767Z.
Calculation as of: 2026-10-06T16:28:24.767Z.
Quote observation: 2026-10-06T16:25:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 954f90b5803147d7e77bb33cb230df589f2ac0b2215919e8afc4fbf9605c1a4a
EARNINGS YIELD
N/A
Market Cap
$238.23M
Earnings Yield
N/A
TTM Avg
11.64%
3Y Avg
12.85%
5Y Avg
11.39%
Market Cap
$221.87M
Earnings Yield
N/A
TTM Avg
9.26%
3Y Avg
9.26%
5Y Avg
9.26%
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Profound Medical Corp. (PROF) | $228.93M | N/A | N/A | N/A | N/A |
| Biodesix, Inc. (BDSX)vs › | $230.08M | N/A | N/A | N/A | N/A |
| MacroGenics, Inc. (MGNX)vs › | $233.59M | N/A | 5.21% | 5.21% | 5.21% |
| BioAge Labs Inc. (BIOA)vs › | $232.72M | N/A | N/A | N/A | N/A |
| High Tide Inc. (HITI)vs › | $236.81M | N/A | N/A | N/A | N/A |
| SIGA Technologies, Inc. (SIGA)vs › | $238.23M | N/A | 11.64% | 12.85% | 11.39% |
| Keros Therapeutics, Inc. (KROS)vs › | $221.87M | N/A | 9.26% | 9.26% | 9.26% |
| InflaRx N.V. (IFRX)vs › | $238.61M | N/A | N/A | N/A | N/A |
| Akebia Therapeutics, Inc. (AKBA)vs › | $239.42M | N/A | N/A | N/A | N/A |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $239.92M | N/A | N/A | N/A | N/A |
Earnings Yield
N/A
EPS ÷ Price
P/E Ratio
N/A
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
